For example, the ROCK inhibitor GSK269962A was found to effectively inhibit the progression of melanoma cell lines [68], and the combination of an epidermal growth factor receptor inhibitor and GSK269926A impaired autophagosome clearance, providing a new strategy for triple‐negative breast cancer treatment [69]. This evidence concerns the gene EGFR and melanoma.